VERAXA Biotech AG (NASDAQ: VRXA) announced on July 20 that it has received Scientific Advice from Germany's Paul-Ehrlich-Institute (PEI), providing regulatory feedback that supports the company's proposed development strategy for its lead BiTAC-TCE program. The advice offers early guidance on the biological rationale, safety assessments, and non-clinical development plan for the novel therapeutic platform, which VERAXA believes will help reduce development uncertainty by providing greater clarity before advancing toward clinical studies (https://ibn.fm/zBiDU).
The regulatory milestone follows encouraging preclinical data presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting, and represents continued progress in manufacturing and development as the company advances next-generation antibody therapeutics for cancer. VERAXA is building a diversified oncology pipeline that includes bispecific T-cell engagers, antibody-drug conjugates (ADCs), and other engineered antibody formats.
Scientific Advice procedures allow drug developers to consult with regulatory experts before clinical trials begin, helping companies align their development strategies with regulatory expectations regarding safety, tolerability, and efficacy. For VERAXA, this feedback is a critical step in derisking the development pathway for its BiTAC-TCE platform, which is designed to harness the body's immune system to target and destroy cancer cells more effectively.
The company's lead BiTAC-TCE candidate has shown promising preclinical results, and the positive regulatory feedback from PEI may accelerate the timeline for initiating first-in-human studies. VERAXA continues to leverage its proprietary technology to create novel therapies that address unmet medical needs in oncology. For more information, visit the company's newsroom at https://ibn.fm/VRXA.
The advancement of the BiTAC-TCE program underscores VERAXA's commitment to developing innovative cancer treatments and highlights the importance of early regulatory engagement in the drug development process. By obtaining scientific advice, the company can better navigate the complex regulatory landscape and focus resources on the most promising candidates.
As VERAXA moves forward, the positive feedback from PEI may also provide confidence to investors and partners, signaling that the company's development strategy is aligned with regulatory expectations. This milestone positions VERAXA to potentially bring its novel therapies to patients more efficiently and effectively.
